Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

H3.3K27M-specific peptide vaccine

A vaccine composed of a peptide derived from histone H3.3 containing the amino acid substitution mutation lysine (Lys) 27-to-methionine (H3.3K27M), with potential immunoactivating and antineoplastic activities. Upon administration of the H3.3K27M-specific peptide vaccine, the immune system may exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against H3.3K27M-expressing tumor cells. The H3.3K27M mutation alters the methylation and acetylation profile of the histone H3 variant H3.3 at Lys 27. Modification of H3.3 at Lys 27 regulates gene expression, and the H3.3K27M mutation occurs in a variety of cancer cell types.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	H3.3K27M peptide vaccine

H3.3K27M-specific peptide vaccine

Search NCI's Drug Dictionary